Streetbeat News

CYDY

Cytodyn Inc

Employees

Industry

Pharmaceutical Preparation Manufacturing

Open

0.13

Mkt cap

168M

Volume

1.1M

High

0.15

P/E Ratio

-6.90

52-wk high

0.36

Low

0.13

Div yield

N/A

52-wk low

0.10

CytoDyn has submitted a clinical protocol to the FDA and initiated a pre-clinical study targeting glioblastoma. This marks a significant step in the company's efforts to develop treatments for this aggressive form of brain cancer.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:44 pm

CytoDyn Inc. has announced the appointment of Jacob Lalezari as its new CEO, effective January 26, 2024. Additionally, Mitchell Cohen has been appointed as the interim CFO, starting from February 1, 2024. These executive changes are part of the company's leadership transition plan.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.